Latest / Glaucoma, Vision & Longevity: Supplements & Science / Your Eye Pressure May Look Fine at the Doctor — While Hidden Spikes at Home Still Drive Glaucoma Progression

Transcript

Your Eye Pressure May Look Fine at the Doctor — While Hidden Spikes at Home Still Drive Glaucoma Progression · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Your eye pressure may look fine at the doctor, while hidden spikes at home still drive glaucoma progression.
• 0:06
  SPEAKER_00: Yes, a reassuring pressure reading in the clinic can miss pressure changes that happen during the rest of the day.
• 0:13
  SPEAKER_00: A study published online on September 30th, 2026 found that two new measures of pressure above a patient's own target were associated with faster visual field decline when calculated from home readings, but not from office readings.
• 0:29
  SPEAKER_00: The result is important, but it does not prove that pressure spikes cause the damage or that home monitoring prevents it.
• 0:37
  SPEAKER_00: The key idea is simple.
• 0:38
  SPEAKER_00: Glaucoma care may learn more from a pattern of pressure readings than from one reading at an appointment.
• 0:44
  SPEAKER_00: But today's home devices take occasional readings, not continuous measurements, and the study's pressure burden measures are still early research tools.
• 0:54
  SPEAKER_00: What the September 30th, 2026 study found.
• 0:58
  SPEAKER_00: The study, in-office and remote intraocular pressure metrics associated with visual field progression in treated open angle glaucoma, compared pressure measurements taken at home with measurements recorded during routine clinic care.
• 1:12
  SPEAKER_00: It asked whether different ways of summarizing pressure were associated with how quickly visual field test results changed over time.
• 1:21
  SPEAKER_00: Its most notable finding was that average pressure and maximum pressure were not significantly associated with visual field decline in this sample, whether measured at home or in the clinic.
• 1:33
  SPEAKER_00: However, two measures that considered pressure relative to each patient's individual treatment target, average and total excess above that target, were associated with faster decline in home readings.
• 1:46
  SPEAKER_00: That distinction matters.
• 1:48
  SPEAKER_00: This was a retrospective association study, not a trial that assigned patients to home monitoring or showed that reducing pressure burden prevents progression.
• 1:56
  SPEAKER_00: The study can identify a signal worth investigating.
• 1:59
  SPEAKER_00: It cannot establish cause and effect.
• 2:02
  SPEAKER_00: Reconstructing the study population and measurements, the researchers reviewed records from 397 treated patients with 777 eyes at Johns Hopkins University and the University of Utah.
• 2:16
  SPEAKER_00: The final analysis included 94 patients and 150 eyes after exclusions.
• 2:21
  SPEAKER_00: Patients had used an eye care home rebound tonometer between October 2018 and September 2024.
• 2:27
  SPEAKER_00: The analysis focused on patients with open angle glaucoma and excluded several other glaucoma types, including angle closure, traumatic, and uveitic glaucoma.
• 2:37
  SPEAKER_00: Who was included?
• 2:39
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 2:44
  SPEAKER_00: The mean visual field result indicates a wide spread of glaucoma severity, not one uniform stage.
• 2:50
  SPEAKER_00: The paper does not report how many eyes fell into each stage, so the average cannot be used to reconstruct those percentages.
• 2:59
  SPEAKER_00: What treatment were patients receiving?
• 3:01
  SPEAKER_00: All participants were treated for glaucoma, and the researchers restricted the clinical record data to periods when treatment was consistent with the home measurement period.
• 3:11
  SPEAKER_00: Most patients were using at least one pressure-lowering eye drop.
• 3:15
  SPEAKER_00: Before the home monitoring period, many eyes had also undergone procedures, including cataract surgery, selective laser trabeculoplasty, trabeculectomy, or microinvasive glaucoma surgery.
• 3:27
  SPEAKER_00: These procedure categories can overlap.
• 3:30
  SPEAKER_00: Each patient's target pressure was set by the treating glaucoma specialist as part of routine care.
• 3:36
  SPEAKER_00: The target was intended to reflect factors such as disease severity, structural damage, starting pressure, and the clinician's judgment.
• 3:44
  SPEAKER_00: The paper analyzed target-based measures in 142 eyes, but the accessible report does not give a cohort-wide average target pressure.
• 3:53
  SPEAKER_00: In other words, it does not support a claim that the group's mean target was a particular number.
• 3:59
  SPEAKER_00: That missing average is important.
• 4:01
  SPEAKER_00: A target is not a universal biological boundary.
• 4:04
  SPEAKER_00: It is a clinical estimate that should be revisited if the eye continues to worsen.
• 4:09
  SPEAKER_00: Glaucoma guidelines likewise describe target pressure as individual rather than one fixed number for everyone.
• 4:17
  SPEAKER_00: How much home and clinic monitoring was done?
• 4:20
  SPEAKER_00: Patients were trained to use the eye care home and instructed to take readings at least four times during waking hours, from waking to 10 a.m., 10 a.m.
• 4:28
  SPEAKER_00: to 2 p.m., 2 p.m.
• 4:30
  SPEAKER_00: to 6 p.m., and 6 p.m.
• 4:32
  SPEAKER_00: until sleep.
• 4:33
  SPEAKER_00: Each included eye had at least seven days of home readings.
• 4:37
  SPEAKER_00: Readings beyond 10 days were excluded from the analysis.
• 4:41
  SPEAKER_00: Patients actually made a median of 4.9 home measurements per day per eye, with an average monitoring period of 8.6 days, standard deviation 1.0.
• 4:52
  SPEAKER_00: Multiplying those summary figures gives a rough estimate of about 42 readings per eye, but that is a calculation, not the reported total for every participant.
• 5:01
  SPEAKER_00: Clinic pressure records included a median of 15.5 visits per eye, spanning nearly five years on average.
• 5:08
  SPEAKER_00: Office readings came from routine care and could use Goldman Applination Tonometry, a clinic eye care rebound device, or a tonopen.
• 5:16
  SPEAKER_00: Thus, the clinic data were not all collected with one instrument.
• 5:20
  SPEAKER_00: Visual field progression was estimated from at least three reliable Humphrey visual field tests using the 24-2 CETA program.
• 5:29
  SPEAKER_00: Eyes were excluded if there were fewer than three reliable tests or if the first to last test interval was less than one year.
• 5:36
  SPEAKER_00: The average eye had 5.82 visual field tests, standard deviation 2.82 over a mean follow-up of about six years.
• 5:44
  SPEAKER_00: The mean visual field mean deviation slope was minor.49 decibels per year, standard deviation 0.67, the median was minus 0.18 decibels per year.
• 5:55
  SPEAKER_00: The pressure readings themselves, the average pressure was similar across home and office measurements.
• 6:02
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 6:07
  SPEAKER_00: The average pressure did not differ significantly across methods, p equals 0.62.
• 6:13
  SPEAKER_00: Other standard summaries did differ across the three measurement contexts.
• 6:17
  SPEAKER_00: The difference between the pooled home readings and the daily home averages is especially useful to understand.
• 6:23
  SPEAKER_00: Averaging by day compresses extremes.
• 6:26
  SPEAKER_00: A high or low reading on one day contributes less to the daily average summary than it does to the all readings pooled summary.
• 6:33
  SPEAKER_00: The study's table reports the office standard deviation as 2.91 mm with a standard deviation of 2.52.
• 6:41
  SPEAKER_00: The prose gives 2.62.
• 6:43
  SPEAKER_00: That small discrepancy does not change the main finding, but it is worth noting when reconstructing the data set.
• 6:49
  SPEAKER_00: What PMAT, AIE, and TI mean?
• 6:53
  SPEAKER_00: The study adapted an idea from continuous glucose monitoring.
• 6:57
  SPEAKER_00: It asked not only what is the average, but also how often and by how much did a reading exceed a chosen limit.
• 7:03
  SPEAKER_00: Percentage of measurements above threshold, PMAT, the share of readings above a chosen pressure.
• 7:09
  SPEAKER_00: If 14 of 100 readings are above the limit, the PMAT is 14%.
• 7:14
  SPEAKER_00: Average intraocular pressure excess, AIE, how far above the threshold the above threshold readings were, on average.
• 7:22
  SPEAKER_00: If readings exceed a 15mm Hz threshold by 1, 2, and 3 mmHg, their average excess is 2 mmHg.
• 7:29
  SPEAKER_00: Total intraocular pressure excess, i.e., a combined measure of how often and how far readings exceeded the threshold.
• 7:36
  SPEAKER_00: Repeated or larger exceedances contribute more than rare, small exceedances.
• 7:41
  SPEAKER_00: The study calculated these measures at 12, 15, 18, and 21 mm, and at each patient's physician set target.
• 7:48
  SPEAKER_00: It also calculated home measures in two ways, across the entire monitoring period absolute, and as daily summaries averaged over the monitoring period daily.
• 7:59
  SPEAKER_00: Important limitation PMAT is the percentage of measurements above a threshold, not the percentage of hours or days above it.
• 8:06
  SPEAKER_00: TI is not a direct measurement of a continuous MIMAG hours pressure dose.
• 8:11
  SPEAKER_00: Four or five sampled readings in a day cannot reveal exactly how long pressure stayed high between readings, or what happened during sleep.
• 8:19
  SPEAKER_00: The exact statistical relationships reported, a negative coefficient means that a higher pressure metric was associated with a more negative, faster worsening visual field slope.
• 8:31
  SPEAKER_00: It does not mean that raising that metric by one unit causes that amount of damage.
• 8:36
  SPEAKER_00: Standard pressure measures, none of the study's standard pressure summaries was significantly associated with visual field slope.
• 8:43
  SPEAKER_00: The reported coefficients, confidence intervals, and p-values were, for the full table, please open this article on VisualFieldtest.com.
• 8:52
  SPEAKER_00: These are results from the published study's generalized estimating equation models, which accounted for the fact that some patients contributed both eyes.
• 9:00
  SPEAKER_00: The models were described as unadjusted association models.
• 9:04
  SPEAKER_00: Threshold-based measures.
• 9:06
  SPEAKER_00: The strongest and most consistent signal was for home AIE and TIE at the patient-specific target.
• 9:13
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 9:17
  SPEAKER_00: At fixed thresholds of 12, 15, and 18 mmhergrams, PMAT, AIE, and TIE were not reported as significantly associated with visual field progression.
• 9:27
  SPEAKER_00: AIE at 21 mmHg was also not significant.
• 9:31
  SPEAKER_00: Office-based versions of the threshold metrics were not significantly associated with progression.
• 9:36
  SPEAKER_00: Office AIE at the individualized target came close, but did not meet the conventional significance cutoff, P equals 0.053.
• 9:45
  SPEAKER_00: The published article's narrative does not state the exact coefficient and p-value for every non-significant threshold-based result.
• 9:53
  SPEAKER_00: Those values should not be guessed.
• 9:55
  SPEAKER_00: Also, the report notes multiple comparisons.
• 9:58
  SPEAKER_00: Some nominally significant results may not remain significant after correction.
• 10:02
  SPEAKER_00: The p-values of 0.048 and 0.035 in particular are modest signals, not decisive proof.
• 10:09
  SPEAKER_00: Which threshold performed best?
• 10:11
  SPEAKER_00: There is no single threshold that was best for every metric.
• 10:14
  SPEAKER_00: For AIE and TIE, the clearest and most consistent findings were at the patient's specific target.
• 10:20
  SPEAKER_00: For PMAT, the significant finding was at 21 mmHD, not at the individual target.
• 10:25
  SPEAKER_00: The standard measures, mean, maximum, and variability, were not significant at any measurement location.
• 10:33
  SPEAKER_00: That pattern suggests that how much pressure exceeded a patient's own target may carry more information than a one-size-fits-all cutoff.
• 10:41
  SPEAKER_00: But the 21mm herd jung PMAT result is also intriguing.
• 10:45
  SPEAKER_00: It may reflect a small subset with high readings rather than a general pressure rule for everyone.
• 10:50
  SPEAKER_00: Why can glaucoma progress when average treated pressure is only 13 to 14 millimeter grams?
• 10:56
  SPEAKER_00: Lowering pressure reduces glaucoma risk, but it does not guarantee that damage stops.
• 11:02
  SPEAKER_00: The early manifest glaucoma trial found that each 1 mm HER of higher follow-up pressure was associated with an 11% higher hazard of progression, while pressure fluctuation was not independently associated in that analysis.
• 11:16
  SPEAKER_00: The United Kingdom glaucoma treatment study also found that pressure lowering treatment can reduce progression risk.
• 11:22
  SPEAKER_00: The clinical lesson is that pressure matters, but the same pressure does not imply the same risk for every optic nerve.
• 11:29
  SPEAKER_00: Several explanations can coexist.
• 11:32
  SPEAKER_00: The target may not be low enough for that eye.
• 11:34
  SPEAKER_00: A target is a working estimate, not a guarantee of stability.
• 11:38
  SPEAKER_00: If repeatable visual field or optical coherence tomography change continues, the treatment target may need reassessment.
• 11:45
  SPEAKER_00: More advanced damage often calls for a lower target.
• 11:49
  SPEAKER_00: The office reading may miss a different time of day.
• 11:52
  SPEAKER_00: Pressure changes across the day with posture and potentially during sleep.
• 11:56
  SPEAKER_00: A reading at one daytime appointment does not establish the full daily pattern.
• 12:01
  SPEAKER_00: The nerve may be unusually vulnerable.
• 12:04
  SPEAKER_00: Thin corneas, corneal biomechanics, age, optic nerve anatomy, vascular factors, and prior damage can influence risk or the interpretation of pressure readings.
• 12:14
  SPEAKER_00: A low recorded pressure is not proof that an individual eye is safe.
• 12:19
  SPEAKER_00: Progression measurements are noisy, visual field results vary, and a slope based on a limited number of tests can be imprecise.
• 12:26
  SPEAKER_00: The study's mean slope of minus zero, 49 decibels per year, should not be interpreted as every eye steadily losing vision at that rate.
• 12:35
  SPEAKER_00: Some injury may not be pressure driven.
• 12:37
  SPEAKER_00: Pressure is an important treatable risk factor, but it is not the only possible influence on an individual's disease course.
• 12:44
  SPEAKER_00: The 2026 study's average pressure near 14 millimeter Horgrags is therefore not paradoxical.
• 12:51
  SPEAKER_00: It is a treated, selected group with a broad range of disease and vulnerability and with visual field slopes that also varied widely.
• 12:59
  SPEAKER_00: Do spikes, fluctuations, or cumulative exposure cause progression?
• 13:04
  SPEAKER_00: The evidence does not point to one settled answer.
• 13:07
  SPEAKER_00: It depends on the study population, how pressure was measured, the time span, and whether the analysis accounted for average pressure and treatment changes.
• 13:16
  SPEAKER_00: Mean pressure matters.
• 13:18
  SPEAKER_00: The strongest causal evidence remains that lowering intraocular pressure reduces risk or slows progression.
• 13:25
  SPEAKER_00: Randomized trials, such as the Early Manifest Glaucoma trial and the United Kingdom glaucoma treatment study support pressure reduction as a treatment strategy.
• 13:34
  SPEAKER_00: This is different from proving that any one short-lived spike causes damage.
• 13:39
  SPEAKER_00: A pressure peak could matter, but a peak alone is not proof.
• 13:43
  SPEAKER_00: In a retrospective 24-hour monitoring study of 29 patients, the average 24-hour peak was 4.9 mm Hz higher than the peak recorded in the clinic.
• 13:54
  SPEAKER_00: Other 24-hour studies have found peaks outside ordinary clinic hours, including overnight or around waking.
• 14:00
  SPEAKER_00: This shows how a clinic schedule can miss pressure elevations.
• 14:04
  SPEAKER_00: It does not establish that every missed peak damages the nerve.
• 14:09
  SPEAKER_00: A study of 148 patients with untreated primary open-angle glaucoma, whose clinic readings were below below 21 millimeter grams, performed pressure measurements through the day and night in sitting and lying positions.
• 14:22
  SPEAKER_00: Such work supports the possibility that pressure measured in a chair during clinic hours is not the same as pressure when supine or asleep.
• 14:31
  SPEAKER_00: Fluctuation has produced conflicting results.
• 14:34
  SPEAKER_00: The advanced glaucoma intervention study reported an association between larger long-term pressure fluctuation and visual field worsening, with the association appearing especially relevant in eyes with lower mean pressures.
• 14:48
  SPEAKER_00: But its results have not been uniform across all cohorts.
• 14:52
  SPEAKER_00: The early manifest glaucoma trial found that fluctuation was not independently associated with progression after accounting for mean pressure.
• 15:00
  SPEAKER_00: In the collaborative initial glaucoma treatment study, the relationship between pressure variability and field decline differed between medication-treated and surgically treated eyes.
• 15:12
  SPEAKER_00: A recent United Kingdom glaucoma treatment study analysis also examined different forms of pressure fluctuation, including daytime and longer-term variation.
• 15:22
  SPEAKER_00: Taken together, these studies do not establish a universal, independently damaging effect of fluctuation.
• 15:29
  SPEAKER_00: Continuous contact lens sensor results are suggestive, not definitive.
• 15:34
  SPEAKER_00: A study of 445 older adults with glaucoma found that certain overnight and daytime patterns from a contact lens sensor were associated with prior visual field progression, even after adjustment for several factors.
• 15:46
  SPEAKER_00: However, the sensor records changes related to the eye's shape rather than a direct pressure value in Mimi to her grangs.
• 15:54
  SPEAKER_00: The study also related a monitoring period to progression that had already occurred.
• 15:59
  SPEAKER_00: It supports further study of 24-hour patterns, but does not prove that sensor-detected peaks caused future loss.
• 16:06
  SPEAKER_00: Home telometry has shown potential, but with the same causal limits.
• 16:11
  SPEAKER_00: Earlier studies using home telometry have found that peak pressure, larger home ranges, or diurnal variation can be associated with progression in some groups.
• 16:21
  SPEAKER_00: A three-day home monitoring study, for example, found higher average and peak pressure and larger pressure ranges in eyes classified as progressing.
• 16:30
  SPEAKER_00: These are useful observations, but differences in study design and patient selection limit how confidently they can be generalized.
• 16:38
  SPEAKER_00: The most biologically plausible model.
• 16:42
  SPEAKER_00: Strong inference, glaucoma damage is more likely to reflect a pressure exposure over time than a single isolated reading, especially if the pressure is repeatedly or persistently above what that particular nerve can tolerate.
• 16:55
  SPEAKER_00: A very high or sustained peak may contribute disproportionately, but an isolated spike that is brief and not repeated is less clearly important.
• 17:04
  SPEAKER_00: In that model, the most biologically meaningful quantity would be something like time-weighted pressure excess above an individual's tolerance, while allowing for the possibility that damage rises nonlinearly at higher pressures.
• 17:18
  SPEAKER_00: That is a reasoned interpretation, not an established clinical standard.
• 17:23
  SPEAKER_00: The new studies AIE and TIE are proxies for that idea.
• 17:27
  SPEAKER_00: They are not yet a validated measurement of the eye's actual cumulative pressure dose.
• 17:32
  SPEAKER_00: Could an eye measuring 10 to 12 millimeter herogs in clinic reach substantially higher pressure at home?
• 17:38
  SPEAKER_00: Yes, it is plausible.
• 17:40
  SPEAKER_00: Across the 150 eyes in the 2026 study, the average of the eye of the highest home readings was about 20 mmhergrams, even though the average pressure across home readings was about 13.9 millimeter hergrams.
• 17:53
  SPEAKER_00: The study also reported a mean home range of about 10.5 millimeter hergrams when measurements were pooled across the monitoring period.
• 18:01
  SPEAKER_00: Those are cohort averages, not the frequency of high readings among people whose clinic pressure was specifically 10 to 12 millimeter herdrang.
• 18:09
  SPEAKER_00: Other 24-hour monitoring data likewise show that out-of-office peaks can exceed clinic peaks.
• 18:16
  SPEAKER_00: But no cited study gives a dependable percentage for the exact question.
• 18:20
  SPEAKER_00: Among treated patients whose clinic pressure is 10 to 12, how many exceed 15 or 18 at home?
• 18:27
  SPEAKER_00: Informed estimate, not a measured study result.
• 18:31
  SPEAKER_00: Among patients selected for home monitoring, because glaucoma is difficult to control, perhaps about one-third to one half of those with a usual clinic reading of 10 to 12 mmHg grips could record at least one reading of 15 mmH or higher over a week.
• 18:47
  SPEAKER_00: Perhaps about 1 in 10 to 1 in 5 could record at least one reading of 18 mmHz or higher.
• 18:54
  SPEAKER_00: These estimates are uncertain, depend on the device and the times measured, and should not be used to predict an individual patient's readings.
• 19:02
  SPEAKER_00: A peak on a home tonometer does not automatically mean the eye spent a long time at that pressure.
• 19:08
  SPEAKER_00: It also does not by itself prove that the peak caused damage.
• 19:12
  SPEAKER_00: What an intraocular pressure burden could mean.
• 19:16
  SPEAKER_00: The analogy to glucose monitoring is attractive.
• 19:19
  SPEAKER_00: Instead of saying only your reading today is 12, a clinician might eventually say, During the monitored week, 14% of your readings were above your target, and the combined size of those exceedences was that could make pressure control easier to understand and might reveal patterns hidden by occasional appointments.
• 19:38
  SPEAKER_00: But there is a crucial difference.
• 19:41
  SPEAKER_00: Glucose monitors provide repeated near-continuous readings, while home tonometers generally provide discrete samples.
• 19:49
  SPEAKER_00: 14% of readings above target is not the same as 14% of the week above target.
• 19:54
  SPEAKER_00: A future glaucoma burden measure would need to account for how many readings were taken and when, how far readings exceeded the patient's target, how long the elevations lasted, day-to-day variation and overnight pressure, the eye's stage of damage and susceptibility, whether pressure was high before or after treatment changes.
• 20:16
  SPEAKER_00: The 2026 paper is an early attempt at this kind of personalized summary.
• 20:21
  SPEAKER_00: Its tie measure combines frequency and magnitude, but does not directly measure duration.
• 20:26
  SPEAKER_00: How dependable is eye care home?
• 20:29
  SPEAKER_00: Home telometry can add useful data, but it should not be treated as an exact substitute for Goldman applination telonometry.
• 20:36
  SPEAKER_00: A 2026 systematic review and meta-analysis found no significant average bias between eye care home and Goldman readings across studies.
• 20:45
  SPEAKER_00: However, individual measurements had wide limits of agreement, approximately smise 5mm her grabs, and results varied considerably among studies.
• 20:54
  SPEAKER_00: In practical terms, the device may be close on average across a group, but differ meaningfully for a particular eye or person.
• 21:01
  SPEAKER_00: Factors that matter include corneal thickness and biomechanics.
• 21:06
  SPEAKER_00: A person's cornea can influence tonometer readings.
• 21:10
  SPEAKER_00: The review found substantial variability, and comparison studies have reported that central corneal thickness relates to the difference between rebound and Goldman measurements.
• 21:20
  SPEAKER_00: There is no simple universal correction that makes every device reading exact.
• 21:25
  SPEAKER_00: Technique, proper alignment, and positioning matter.
• 21:28
  SPEAKER_00: Training in a clinic comparison can help identify whether a person can obtain consistent readings.
• 21:33
  SPEAKER_00: In one reliability study, up to 80% of patients' readings were within 3mm harams of a clinician's reading before a week of home monitoring, and up to 90% were within 3 mm afterward.
• 21:46
  SPEAKER_00: Time of day a monitoring schedule that samples only clinic hours can miss early morning, evening, or overnight patterns.
• 21:54
  SPEAKER_00: Sleep, the eye care home used in the study, required the person to be awake and operate the device.
• 22:00
  SPEAKER_00: It did not continuously measure pressure during sleep.
• 22:02
  SPEAKER_00: Adherence.
• 22:03
  SPEAKER_00: A device only helps if the patient can and will use it correctly.
• 22:07
  SPEAKER_00: A prospective home tonometry cohort found varied adherence even with training.
• 22:13
  SPEAKER_00: Selection effects.
• 22:14
  SPEAKER_00: Home tonometry is often prescribed to patients who are already difficult to manage, progressing, or suspected of having unusual pressure patterns.
• 22:23
  SPEAKER_00: Those patients are not representative of every person with glaucoma.
• 22:27
  SPEAKER_00: The 2026 study itself was drawn from patients whom specialists had already selected for home monitoring.
• 22:34
  SPEAKER_00: How many readings and days are enough?
• 22:37
  SPEAKER_00: There is no proven universal number that guarantees a reliable estimate for every patient.
• 22:43
  SPEAKER_00: A prospective study that monitored patients over several weeks concluded that four readings per day for seven days could provide a robust estimate of diurnal pressure patterns that otherwise might require several weeks of observation.
• 22:57
  SPEAKER_00: A separate real-world study of home tonometry reported trials averaging about seven days and about four readings per day.
• 23:05
  SPEAKER_00: These findings make a week of structured daytime sampling a reasonable starting profile, not a permanent guarantee that the same pattern will hold year-round.
• 23:15
  SPEAKER_00: The September 2026 study's average of about 4.9 readings per day over 8.6 days is broadly consistent with that approach.
• 23:24
  SPEAKER_00: It cannot establish whether a week fully captures a stable pressure pattern across different seasons, routines, medication adherence, or later changes in disease.
• 23:34
  SPEAKER_00: Periodic monitoring may be more useful than assuming one week represents every week.
• 23:40
  SPEAKER_00: Practical interpretation.
• 23:42
  SPEAKER_00: A week with at least four readings spaced across waking hours appears reasonable for an initial profile.
• 23:48
  SPEAKER_00: If readings are inconsistent, technique is uncertain, symptoms or disease changes arise, or a major treatment change occurs, the ophthalmologist may consider repeating or extending monitoring.
• 24:00
  SPEAKER_00: That is an evidence-informed approach, not a tested prescription for everyone.
• 24:05
  SPEAKER_00: Who might benefit most from home monitoring?
• 24:08
  SPEAKER_00: Home tonometry is most likely to add value when a clinician needs information that routine appointments are unlikely to provide.
• 24:16
  SPEAKER_00: Patients progressing despite apparently low clinic pressure.
• 24:20
  SPEAKER_00: People with normal tension glaucoma, particularly if progression continues and timing of the peak is uncertain.
• 24:26
  SPEAKER_00: Patients with advanced disease, for whom a missed pressure pattern may have greater consequences.
• 24:33
  SPEAKER_00: Patients with suspected early morning or out-of-office peaks.
• 24:37
  SPEAKER_00: Patients after trabeculectomy or other pressure-lowering surgery when the clinician wants to understand both pressure levels and variability.
• 24:45
  SPEAKER_00: People assessing whether medication, selective laser trabeculoplasty, or surgery changed pressure patterns.
• 24:52
  SPEAKER_00: Small studies suggest that eye care home can help assess treatment-related pressure changes after medication or laser treatment.
• 25:00
  SPEAKER_00: However, these studies do not establish that monitoring itself improves long-term vision outcomes.
• 25:07
  SPEAKER_00: Trabeculectomy can change more than average pressure.
• 25:10
  SPEAKER_00: Studies using day and night pressure profiles have reported reductions in mean pressure and day-to-day variability after filtering surgery.
• 25:18
  SPEAKER_00: Other studies have found that postoperative peak pressure and fluctuation relate to features of the functioning drainage bleb.
• 25:26
  SPEAKER_00: The specific results vary by patient group and surgical context.
• 25:31
  SPEAKER_00: Home readings should be reviewed with the treating eye care professional.
• 25:35
  SPEAKER_00: Patients should not change medication or dosing times on their own in response to a single high or low reading.
• 25:41
  SPEAKER_00: What the study does and does not establish.
• 25:45
  SPEAKER_00: Established evidence.
• 25:47
  SPEAKER_00: Lowering pressure reduces glaucoma risk and progression risk in major clinical studies.
• 25:52
  SPEAKER_00: Pressure varies, and measurements taken during clinic hours do not capture every daily or nighttime pressure pattern.
• 25:59
  SPEAKER_00: EyeCare Home can provide additional out-of-office readings, but a reading is not interchangeable with Goldman for every individual.
• 26:07
  SPEAKER_00: The 2026 study found associations between faster visual field decline and home AIE and TIE at individualized targets, while standard pressure summaries were not significantly associated.
• 26:21
  SPEAKER_00: Strong inference.
• 26:23
  SPEAKER_00: For selected patients whose glaucoma worsens despite reassuring clinic readings, home pressure profiles can provide clinically useful additional information.
• 26:33
  SPEAKER_00: A personalized measure of repeated pressure excess may be more informative than a uniform cutoff across patients with different disease stages and targets.
• 26:42
  SPEAKER_00: Time-integrated pressure excess above individual tolerance is a more biologically plausible exposure measure than one isolated reading, though peak height and the nerve susceptibility may also matter.
• 26:54
  SPEAKER_00: Informed speculation.
• 27:05
  SPEAKER_00: The estimates above are extrapolations, not measured rates.
• 27:09
  SPEAKER_00: Home data may detect a pressure pattern months earlier than a schedule of occasional clinic measurements in some patients.
• 27:15
  SPEAKER_00: Periodic home monitoring could become a routine option for selected high-risk patients, but widespread use would depend on cost, training, reimbursement, device performance, and evidence that the information changes care in a way that preserves vision.
• 27:31
  SPEAKER_00: How likely is home pressure monitoring to matter clinically?
• 27:35
  SPEAKER_00: The following are judgment estimates, not probabilities calculated by the 2026 study.
• 27:41
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 27:45
  SPEAKER_00: These estimates should not be read as promises.
• 27:48
  SPEAKER_00: The first depends heavily on selecting the right patients.
• 27:52
  SPEAKER_00: Many people with stable mild glaucoma may gain little from repeated home readings.
• 27:57
  SPEAKER_00: The second reflects the biological plausibility of a cumulative load and suggestive observational data, balanced against conflicting evidence about whether fluctuation independently predicts damage.
• 28:09
  SPEAKER_00: The last two are forecasts, not study outcomes.
• 28:12
  SPEAKER_00: Is a single eye pressure reading at the doctor becoming obsolete?
• 28:17
  SPEAKER_00: No, not obsolete, but increasingly incomplete for some patients.
• 28:22
  SPEAKER_00: A standardized office measurement remains useful, especially when compared with prior readings taken under similar conditions.
• 28:29
  SPEAKER_00: It should not be treated as a full description of a patient's pressure across the day and night.
• 28:34
  SPEAKER_00: For a patient progressing despite apparently good clinic pressure, the more useful question may be not just what was the pressure today, but what does pressure look like over time and how does that compare with this eye's target?
• 28:47
  SPEAKER_00: An ideal future glaucoma monitoring system would combine average interocular pressure, peak pressure with the time and context recorded, time above an individualized target, magnitude of pressure excess, circadian pattern, including morning and nighttime measurements where feasible, visual field slope, optical coherence tomography, nerve fiber layer slope.
• 29:12
  SPEAKER_00: The likely biological priority is not a single highest number or variability by itself.
• 29:18
  SPEAKER_00: It is repeated pressure exposure, especially the magnitude and duration of pressure above what that particular optic nerve can tolerate, interpreted alongside nerve susceptibility and measured progression.
• 29:30
  SPEAKER_00: That is a reasoned conclusion from current evidence, not yet a validated clinical formula.
• 29:36
  SPEAKER_00: Bottom line, the September 2026 study strengthens the case that home pressure patterns can reveal information missed by routine clinic readings, particularly when the readings are compared with an individual target.
• 29:49
  SPEAKER_00: It does not prove that spikes alone drive progression.
• 29:53
  SPEAKER_00: A single reading is still useful.
• 29:55
  SPEAKER_00: For selected high risk patients, it may no longer be enough on its own.
• 30:00
  SPEAKER_00: All links to sources are available in the text version of this article.
• 30:04
  SPEAKER_00: You can find the full article at visualfieldtest.com.
• 30:08
  SPEAKER_00: Thanks for listening.
• 30:09
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.